Physician profile
Casey M Barnes
NPI 1609352434
$5,337.89
in general payments reported to CMS, 2019-2025
44 companies · $799 in 2025
The $799 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,337 · 2022: $1,264 · 2023: $1,339 · 2024: $599 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.23 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $628.42 | 2021-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $553.92 | 2021-2025 | |
| Abbvie INC. | $471.56 | 2021-2023 | |
| Novo Nordisk INC | $305.03 | 2021-2025 | Wegovy |
| Avion Pharmaceuticals | $280.37 | 2021-2023 | Balcoltra |
| Evofem Biosciences, INC. | $241.01 | 2022-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $226.46 | 2021-2025 | |
| Exeltis, USA INC. | $218.41 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $215.24 | 2021-2022 | |
| Astellas Pharma US INC | $206.88 | 2022-2025 | Veozah, Myrbetriq |
| Millicent US INC | $202.82 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Sumitomo Pharma America, INC. | $149.97 | 2023-2025 | Myfembree |
| Pfizer INC. | $138.35 | 2021-2025 | |
| Daiichi Sankyo INC. | $131.85 | 2021-2023 | Injectafer |
| Currax Pharmaceuticals LLC | $130.35 | 2021-2023 | Contrave, Onzetra Xsail |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $104.71 | 2021-2022 | |
| Bausch Health US, LLC | $85.71 | 2023-2024 | Aplenzin, Wellbutrin |
| Ascend Therapeutics US, LLC | $72.51 | 2022-2023 | |
| Virtus Pharmaceuticals LLC | $72.34 | 2021-2022 | |
| Organon LLC | $66.59 | 2021-2023 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $66.08 | 2021-2025 | Trintellix |
| Scynexis, INC. | $58.75 | 2022 | |
| Mylan Pharmaceuticals INC. | $55.32 | 2021-2022 | |
| Lilly USA, LLC | $54.45 | 2024-2025 | Zepbound, Mounjaro |
| Radius Health, INC. | $54.34 | 2021 | |
| Merck Sharp & Dohme LLC | $50.87 | 2022-2024 | Gardasil 9, Gardasil |
| Axsome Therapeutics, INC. | $50.35 | 2023 | Auvelity |
| Agile Therapeutics, INC. | $49.56 | 2021-2022 | |
| Mission Pharmacal Company | $46.72 | 2021-2023 | Citranatal |
| Myriad Women'S Health, INC. | $43.74 | 2023 | Myrisk |
| Aspira Women'S Health INC | $38.02 | 2022 | |
| Exact Sciences Corporation | $36.30 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $27.87 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $23.70 | 2024 | Freestyle Libre |
| Renovia INC | $20.68 | 2021 | |
| Convatec INC. | $20.59 | 2021 | |
| Allergan, INC. | $20.28 | 2021 | |
| Mckesson Medical-Surgical, INC. | $19.47 | 2023 | |
| Acessa Health INC. | $19.05 | 2021 | |
| Davol INC. | $18.76 | 2024 | Arista Ah Flexitip |
| Asensus Surgical, INC. | $18.74 | 2023 | Senhance |
| Shield Therapeutics INC | $15.59 | 2023 | Accrufer |
| Vertex Pharmaceuticals Incorporated | $13.95 | 2025 | |
| Becton, Dickinson and Company | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.